US2017080143A1PendingUtilityA1
Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases
Est. expiryJan 9, 2032(~5.5 yrs left)· nominal 20-yr term from priority
A61M 1/3609A61M 1/369A61M 2202/206A61M 1/3627A61M 1/3681A61M 1/3672A61M 1/3621A61M 2202/20A61M 2205/054A61M 1/3693A61M 1/3696A61M 2202/203A61M 1/3687A61M 1/36A61M 1/3606A61M 1/14A61M 1/16
39
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with cold plasma and optionally with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An extracorporeal method for treating a blood-borne disease comprising the steps of:
a) removing blood from a subject; b) contacting the blood with an anticoagulant; c) optionally separating the blood into two or more blood fractions; d) optionally modifying the environment of the blood or a blood fraction; e) treating the blood or blood fraction with cold plasma; f) treating the blood or blood fraction with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, centrifugation, microwave, radiation, sonification, or a combination thereof; and g) returning at least a portion of the blood or blood fraction to the subject.
2 . An extracorporeal system comprising:
a) a blood removal port; b) an anticoagulant module; c) a module adapted to modify the environment of blood or a blood fraction; d) a treatment module adapted to administer cold plasma; e) one or more treatment modules adapted to administer hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, radiation, sonification, or a combination thereof; and f) a blood return port.Join the waitlist — get patent alerts
Track US2017080143A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.